Gene · 1633
DCK: deoxycytidine kinase
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. DCK: deoxycytidine kinase. Genes, record 1633. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1633
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P27707 | Deoxycytidine kinase | 260 | 58 | Ensembl, GeneID, HGNC |
Source UniProt
Patents50
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4694917 A1 | 2026-02-18 | 580 | P27707 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 43598 | P27707 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 3297 | P27707 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 2874 | P27707 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 16585 | P27707 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 2874 | P27707 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 3297 | P27707 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 16585 | P27707 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 16585 | P27707 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 16424 | P27707 | Espacenet |
1 to 10 of 50
See all 50 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,397
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | DCK papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 31 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 21 | 2025 |
| P30CA016042 | Cancer Center Support Grant | 19 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 15 | 2025 |
| P30CA043703 | Case Comprehensive Cancer Center Support Grant | 11 | 2025 |
| R01CA132946 | Genomics of AML Prognosis | 10 | 2025 |
| P30AI050409 | Center for AIDS Research at Emory University | 7 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 7 | 2025 |
| P30CA056036 | Translational Research in Cancer | 7 | 2025 |
| P30CA168524 | The University of Kansas Cancer Center | 6 | 2025 |
1 to 10 of 1,397Source NIH's project files
See all 1,397 nih grantsPapers2,658
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Chromosomal Heterogeneity and Enrichment of Mitotic Regulatory Programs Reveal a Therapeutic Vulnerability in Cytarabine-Resistant FLT3-ITD AML. | Curr Issues Mol Biol | 2026 | 42793322 | PubTator, text mining | PubMed |
| A complex mutational signature generated by cytarabine resistance. | NAR Cancer | 2026 | 42630438 | PubTator, text mining | PubMed |
| Folic acid alleviates neuroinflammation after intracerebral hemorrhage by epigenetically regulating the AMPD2/DCK/NF-κB pathway. | Phytomedicine | 2026 | 42542053 | PubTator, text mining | PubMed |
| Metabolic and Molecular Mechanisms of Gemcitabine Resistance in Urothelial Carcinoma. | Cancers (Basel) | 2026 | 42449668 | PubTator, text mining | PubMed |
| Cellular pharmacology of fludarabine: molecular determinants of transport and metabolism. | Front Pharmacol | 2026 | 42239518 | PubTator, text mining | PubMed |
| Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study. | Br J Clin Pharmacol | 2026 | 42220058 | PubTator, text mining | PubMed |
| Epigenetic Biomarkers for Predicting Nucleoside Analog Drug Response and Resistance in Cancer. | Biomolecules | 2026 | 42072708 | PubTator, text mining | PubMed |
| Marine Bioactive Compounds from Functional Seafoods: Pharmacological Mechanisms and Health Applications. | Mar Drugs | 2026 | 41892975 | PubTator, text mining | PubMed |
| Deoxycytidine kinase inhibition: Rewiring tumor nucleotide metabolism for therapeutic gain. | Nucleosides Nucleotides Nucleic Acids | 2026 | 41889017 | PubTator, text mining | PubMed |
| Research progress of plant-derived chemical compounds for overcoming pancreatic cancer drug resistance. | World J Gastroenterol | 2026 | 41810441 | PubTator, text mining | PubMed |
1 to 10 of 2,658
See all 2,658 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1633
GET https://conductscience.org/api/genes/v1/1633/patents?page=2